OCUGEN, INC. Finance Lease, Liability, Undiscounted Excess Amount
OCUGEN, INC. (OCGN) had Finance Lease, Liability, Undiscounted Excess Amount of $444 as of 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2020-11-06
- 2020-09-30: Finance Lease, Liability, Undiscounted Excess Amount $444.00.
- 2020-06-30: Finance Lease, Liability, Undiscounted Excess Amount $809.00.
- 2020-03-31: Finance Lease, Liability, Undiscounted Excess Amount $1.28K.
- 2019-12-31: Finance Lease, Liability, Undiscounted Excess Amount $1.85K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2020-09-30 | $444.00 10-Q · filed 2020-11-06 |
| 2020-06-30 | $809.00 10-Q · filed 2020-08-14 |
| 2020-03-31 | $1.28K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.85K 10-K · filed 2020-03-27 |
| 2019-09-30 | $4.57K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.58K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |